Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C I Edvard Smith

Showing results (141-150 of 186) with videos related to

Pageof 19
Sort By:
Leukemia & Lymphoma|April 25, 2015
A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cellsMaria E Cardona, Oscar E Simonson, Iulian I Oprea, et al.
Nucleic Acid Therapeutics|January 17, 2015
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotidesPeter Järver, Eman M Zaghloul, Andrey A Arzumanov, et al.
Blood Advances|June 4, 2020
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effectsH Yesid Estupiñán, Thibault Bouderlique, Chenfei He, et al.
Journal of Clinical Immunology|September 14, 2007
Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genesAnna Sedivá, C I Edvard Smith, A Charlotta Asplund, et al.
British Journal of Haematology|December 26, 2025
T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemiaMaria L Andersson, Olina Lind, Kia Heimersson, et al.
Clinical Immunology (Orlando, Fla.)|October 21, 2015
Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) geneKarin E Lundin, Abdulrahman Hamasy, Paul Hoff Backe, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 12, 2009
Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategyTaavi Lehto, Rachida Abes, Nikita Oskolkov, et al.
Molecular Therapy. Nucleic Acids|June 9, 2025
Anti-gene oligonucleotides targeting Friedreich's ataxia expanded GAA⋅TTC repeats increase Frataxin expressionNegin Mozafari, Salomé Milagres, Tea Umek, et al.
Molecular Therapy. Nucleic Acids|November 26, 2014
Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified OligonucleotidesSuzan M Hammond, Graham McClorey, Joel Z Nordin, et al.
British Journal of Haematology|August 21, 2018
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodesMarzia Palma, Aleksandra Krstic, Lucia Peña Perez, et al.
Pageof 19

Showing results (141-150 of 186) with videos related to

Sort By:
Pageof 19
Leukemia & Lymphoma|April 25, 2015
A murine model of acute myeloid leukemia with Evi1 overexpression and autocrine stimulation by an intracellular form of GM-CSF in DA-3 cellsMaria E Cardona, Oscar E Simonson, Iulian I Oprea, et al.
Nucleic Acid Therapeutics|January 17, 2015
Peptide nanoparticle delivery of charge-neutral splice-switching morpholino oligonucleotidesPeter Järver, Eman M Zaghloul, Andrey A Arzumanov, et al.
Blood Advances|June 4, 2020
Novel mouse model resistant to irreversible BTK inhibitors: a tool identifying new therapeutic targets and side effectsH Yesid Estupiñán, Thibault Bouderlique, Chenfei He, et al.
Journal of Clinical Immunology|September 14, 2007
Contiguous X-chromosome deletion syndrome encompassing the BTK, TIMM8A, TAF7L, and DRP2 genesAnna Sedivá, C I Edvard Smith, A Charlotta Asplund, et al.
British Journal of Haematology|December 26, 2025
T-cell immunomodulation occurs with different time kinetics during acalabrutinib and zanubrutinib therapy in chronic lymphocytic leukaemiaMaria L Andersson, Olina Lind, Kia Heimersson, et al.
Clinical Immunology (Orlando, Fla.)|October 21, 2015
Susceptibility to infections, without concomitant hyper-IgE, reported in 1976, is caused by hypomorphic mutation in the phosphoglucomutase 3 (PGM3) geneKarin E Lundin, Abdulrahman Hamasy, Paul Hoff Backe, et al.
Journal of Controlled Release : Official Journal of the Controlled Release Society|September 12, 2009
Delivery of nucleic acids with a stearylated (RxR)4 peptide using a non-covalent co-incubation strategyTaavi Lehto, Rachida Abes, Nikita Oskolkov, et al.
Molecular Therapy. Nucleic Acids|June 9, 2025
Anti-gene oligonucleotides targeting Friedreich's ataxia expanded GAA⋅TTC repeats increase Frataxin expressionNegin Mozafari, Salomé Milagres, Tea Umek, et al.
Molecular Therapy. Nucleic Acids|November 26, 2014
Correlating In Vitro Splice Switching Activity With Systemic In Vivo Delivery Using Novel ZEN-modified OligonucleotidesSuzan M Hammond, Graham McClorey, Joel Z Nordin, et al.
British Journal of Haematology|August 21, 2018
Ibrutinib induces rapid down-regulation of inflammatory markers and altered transcription of chronic lymphocytic leukaemia-related genes in blood and lymph nodesMarzia Palma, Aleksandra Krstic, Lucia Peña Perez, et al.
Pageof 19